CHIR98014

Research use only, not for human use.

CHIR 98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.

CHIR98014, also known as CT-98024, is a reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively). It is inactive against a series of other serine/threonine or tyrosine kinases. Through its effects on GSK3, CHIR98014 stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals. CHIR98014 also reduces tau phosphorylation in rat brains and supports Wnt signaling during osteogenesis.

——

——

CHIR98014 | CHIR-98014 | CHIR 98014

Autophagy

CXCR

GSK-3α/β| p70 S6K

Cancer

——

556813-39-9

486.31

C20H17Cl2N9O2

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (257.04 mM)

c1cc(c(cc1Cl)Cl)c1nc(ncc1c1[nH]ccn1)NCCNc1nc(c(cc1)[N+](=O)[O-])N

N2-(2-((4-(2,4-dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine

(-20℃)

With Ice Pack

≥ 2 years